Biodesix, Inc
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services. Its core business combines blood-based clinical tests for physicians with contract development, testing, and consulting services for biopharmaceutical, life sciences, and academic customers. The company uses multi-omic methods, including genomics, proteomics, radiomics, and AI, to develop and commercialize tests that address immediate clinical questions. Revenue is split between Lung Diagnostic Testing and Development Services, with clinical testing as the larger and more established business.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBlood-based diagnostic tests used by healthcare providers to assess lung nodules and related clinical questions.
Custom diagnostic development, testing, and consulting services for biopharma, life sciences, and research partners.
Products
Reported · share of revenue- Diagnostic Tests89.5 %
- Development Services10.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Biodesix sells primarily to healthcare providers and clinicians who order lung diagnostic tests for patients with pulmonary nodules or other lung-related clinical needs. These customers use the tests to improve diagnostic confidence, guide patient management, and support more personalized care decisions. The company also serves biopharmaceutical, life sciences, and academic research organizations that need assay development, biomarker discovery, validation, and clinical trial testing support. In Development Services, customers buy Biodesix’s scientific and operational capabilities to accelerate diagnostics and therapeutic programs, often because they lack in-house infrastructure or want specialized multi-omic expertise.
Order blood-based lung diagnostic tests to help assess pulmonary nodules and improve patient management decisions.
Buy development services, clinical trial sample testing, and biomarker/companion diagnostic support to advance drug and diagnostic programs.
Use Biodesix for assay development, validation, and commercialization support when they need specialized diagnostic capabilities.
Engage the company for translational research, custom testing, and collaborative discovery work.
Not direct buyers in the usual sense, but critical to test adoption because coverage and reimbursement determine access and realized revenue.
Strategy
Biodesix is focused on expanding adoption of its lung diagnostic tests by increasing clinical evidence, reimbursement coverage, and field sales effectiveness. The company is also investing in operational efficiency so that higher test volume translates into better margins and operating leverage. In Development Services, it is trying to broaden relationships with biopharma and research customers, which can create recurring revenue and open opportunities in companion diagnostics and novel target discovery. The broader strategy is to use its multi-omic platform and clinical data assets to build a more durable diagnostics franchise with both commercial and partnership revenue streams.
Clinical volume and payer coverage directly drive realized revenue and determine whether the core testing business can scale.
Higher test volume only creates durable value if the company can lower cost per test and convert scale into operating leverage.
Biopharma and research relationships diversify revenue and can create longer-term opportunities in companion diagnostics and discovery.
Geography
Biodesix is headquartered in the United States and its commercial business is centered on the U.S. healthcare market. The company also markets Development Services to biopharmaceutical customers in the United States and internationally, so that business has a broader geographic reach than the clinical testing franchise. The reports do not disclose a country-by-country revenue split, but the company’s exposure is clearly tied to U.S. reimbursement, Medicare/Medicaid policy, and domestic clinical adoption. International exposure is mainly through business development and research partnerships rather than a large disclosed operating footprint.
Risks
Biodesix depends heavily on payer coverage, reimbursement decisions, and physician adoption, so any slowdown in market acceptance can directly reduce test volume and collections. The company also relies on Medicare, Medicaid, and other federally funded programs, making it vulnerable to government shutdowns or policy changes that delay payments or coverage decisions. Development Services revenue depends on retaining and expanding biopharma relationships, which can be cyclical and competitive. More generally, the business faces supply chain risk, execution risk in scaling sales coverage, and the possibility that new diagnostic products do not achieve sufficient clinical or commercial traction.
- Coverage and reimbursement uncertaintyImpact: HighLikelihood: High
Diagnostic revenue depends on payer decisions, and the company recognizes lung test revenue using estimates of amounts ultimately collectible.
Exposure: Lung Diagnostic Testing
- Commercial adoption riskImpact: HighLikelihood: High
Revenue growth depends on physicians, payers, and patients accepting the clinical utility of the tests.
Exposure: Nodify Lung and other diagnostic tests
- Dependence on Medicare, Medicaid, and federal healthcare programsImpact: HighLikelihood: Medium
A prolonged government shutdown or policy change could delay payments, coverage decisions, or patient access.
Exposure: U.S. clinical testing revenue
- Biopharma customer retention and expansionImpact: MediumLikelihood: Medium
Development Services growth depends on maintaining and expanding relationships with existing customers and winning new ones.
Exposure: Development Services
- Supply chain and single-source supplier dependenceImpact: MediumLikelihood: Medium
Laboratory testing operations can be disrupted by shortages, price increases, or vendor failures.
Exposure: Testing operations and specimen logistics
- Nasdaq listing complianceImpact: MediumLikelihood: Medium
Failure to maintain minimum bid price or other listing standards could affect market access and investor confidence.
Exposure: Capital markets access
Accounting
Judgemental itemsRevenue is recognized using estimated collectible amounts based on payer coverage and historical reimbursement experience, creating estimation risk.
Impact: Can materially affect reported revenue, receivables, and margins
Revenue timing depends on identifying performance obligations and satisfying them over time or at a point in time.
Impact: Can shift revenue between quarters
Management must estimate amounts ultimately expected to be collected for delivered tests.
Impact: Affects revenue, bad debt-like adjustments, and comparability
Non-cash equity awards are a recurring operating expense and can distort underlying cash profitability trends.
Impact: Affects operating expense and net loss
Similar listed companies
Publicly listed companies with a comparable business focus.
NeoGenomics, Inc
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Insight Molecular Diagnostics Inc.
IMDX · In Vitro & In Vivo Diagnostic Substances
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Last updated: 24/09/2026